There is plenty of psychological material that can be examined in the palliative care encounter, despite the fact that it is frequently practiced by doctors with backgrounds outside of mental health training. This case presentation and associated discussion to introduce the psychological aspects of palliative medicine to psychiatrists and psychotherapists is based on the palliative care consultation sought with the multiple objectives of alleviating a patient’s severe death anxiety and persistent dyspnea, as well as helping in the clarification of his end-of-life wishes.

Neuroleptic malignant syndrome (NMS), which has a high morbidity and death rate, is one of the deadly side effects of antipsychotic or antiemetic drugs. The common drugs linked to NMS are identified in this article, along with the etiology of the condition, clinical symptoms, risk factors, laboratory and imaging results, and treatment options.

The disappointing findings from the $100 million National Institutes of Health (NIH) project, the first-ever prevention trial for Alzheimer’s disease, which tested an antiamyloid monoclonal antibody called crenezumab in people with the Paisa mutation, the most common cause of familial, early-onset Alzheimer’s disease.

Paolo Manfredi, chief scientific officer at Relmada Therapeutics, remarked, “This designation further supports the potential of REL-1017 as a paradigm-shifting, novel standalone treatment for MDD, and highlights the significant unmet medical need in a therapeutic area where little has changed over the last several decades: available treatments remain inadequate for the majority of patients with MDD.”

According to Paul Harrison, FRCPsych, of the University of Oxford in England, and colleagues, health records of nearly 1.3 million people, mostly in the US, revealed that risks of cognitive deficit (brain fog), dementia, psychotic disorders, and epilepsy or seizures were elevated at 2 years for adults who had COVID. Adult COVID patients had an increased risk of anxiety and depression in the first six months, but this risk decreased over time, the researchers reported in Lancet Psychiatry.

After reading this article, head over to this quiz to test your understanding of the findings of a triple-blind, crossover study that involved 173 ADHD-diagnosed children between the ages of 7 and 12. Children received daily education in science, social studies, and vocabulary for 25 minutes over the course of two successive sessions.